Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens

International audienceBayesian joint modeling, bivariate toxicity, cumulative probability of toxicity, dose regimen, early phase oncology, pharmacokinetics/pharmacodynamics 1 INTRODUCTION Most phase I dose-finding trials in oncology aim to determine the maximum tolerated dose (MTD), which is defined as the highest dose that does not exceed a predefined probability of dose-limiting toxicity (DLT), in a prespecified observational window. The DLT is a binary outcome defined to summarize the patient's toxicity profile and is usually derived from Moreno Ursino and Marie-Karelle Riviere contributed equally to this study. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made